Antisense Oligomers Modulating FcεRIβ Expression
Solution Overview
Problem
Current treatments for asthma and allergic diseases, such as those involving β-agonists and glucocorticosteroids, come with undesirable side effects and do not effectively address underlying inflammation, and alternative approaches like allergen desensitization are not beneficial for all patients, highlighting a need for new treatments that modulate IgE-mediated immune responses.
Innovation Solution
The use of antisense oligonucleotides targeting the FcεRIβ protein to alter splicing of the MS4A2 gene's pre-mRNA, reducing cell surface expression of the high-affinity IgE receptor (FcεRI) by hybridizing to specific sequences involved in splicing, thereby modulating IgE-mediated immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies using β-agonists and glucocorticosteroids are used to treat asthma and allergic diseases, then inflammatory response is damped and airway smooth muscle is relaxed, but undesirable side effects occur and underlying inflammation is not effectively addressed
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (FcεRIβ protein) that mediates IgE-dependent mast cell signaling. By using antisense oligonucleotides to specifically reduce FcεRIβ expression, the treatment addresses the root cause of allergic responses without the broad-spectrum side effects of glucocorticosteroids or the cardiovascular risks of β-agonists.
Solution Approach 2:
The antisense oligonucleotides act as intermediaries that specifically bind to FcεRIβ mRNA, preventing protein synthesis. This intermediary approach allows selective modulation of the FcεRI signaling pathway without affecting other physiological systems, thereby achieving effective treatment with minimal side effects.
2Duration of action of moving object
If allergen desensitization is used to induce immune tolerance, then some patients experience longer-term alleviation of symptoms, but not all patients benefit and serious adverse side effects occur
Solution Approach 1:
The patent employs preliminary action by pre-reducing FcεRIβ expression levels before allergen exposure can trigger severe responses. The antisense oligonucleotides are administered to establish a reduced baseline of FcεRIβ protein, thereby preventing the cascade that leads to anaphylaxis while providing sustained symptom relief without the unpredictability of desensitization protocols.
3Reliability
If FcεRIβ protein function is enhanced to improve IgE-dependent mast cell signaling, then receptor complex trafficking to cell surface is improved and signaling is amplified, but allergic responses are intensified
Solution Approach 1:
The patent applies inversion by reducing FcεRIβ expression rather than enhancing it. The antisense oligonucleotides specifically target and reduce FcεRIβ mRNA levels, thereby decreasing protein synthesis and ultimately reducing the number of FcεRI receptors on the mast cell surface. This inverse approach dampens the allergic response pathway that would otherwise be intensified by enhanced signaling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces cell surface expression of FcεRI, leading to decreased IgE receptor-dependent degranulation, cytokine release, and mast cell migration, providing a potential treatment for allergic conditions by inhibiting anaphylactic reactions and treating asthma and related diseases.
Implementation Method 1
Hybridization of the antisense oligomer to the FcεRIβ-encoding pre-mRNA alters splicing of the pre-mRNA
Data Source
AI summary
Methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI). Antisense oligomers for modulating splicing of mRNA encoding the FcεRIβ protein, thereby down-regulating cell-surface expression of FcεRI, and uses of the antisense oligomers for inhibiting mast cell degranulation, cytokine release, migration, and proliferation.